AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira ' s Title

AbbVie stock was muted Friday after beating first-quarter expectations as Humira sales continue falling. Skyrizi is catching up, though. The post AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title appeared first on Investor's Business Daily.#abbvie #humira #skyrizilooks #title

Source: Reuters: Health - April 26, 2024 Category: Consumer Health News Source Type: news